Nivolumab Plus Cabozantinib Tops Sunitinib for Renal Cell Carcinoma
Combination therapy superior with respect to progression-free, overall survival and overall response for first-line treatment of advanced RCC.
Renal Cell Carcinoma
ACE2 Pathway Stimulation Enhances VEGF Inhibition in ccRCC, May Help Overcome VEGF Resistance
New study data offer insight on the mechanisms of angiotensin converting enzyme 2 (ACE2) in clear cell renal cell carcinoma (ccRCC).
Palliative Care Use in Advanced Renal Cell Carcinoma Linked to Socioeconomic Groups
Researchers sought to determine accessibility and use of palliative care among patients with advanced renal cell carcinoma.
Oral HIF-2α Inhibitor Belzutifan Upholds Clinical Activity in RCC
Todd Bauer, MD, presents updated data from a phase 1/2 study of the oral hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan.
Sexual Orientation May Influence Choice to Pursue Screening for ‘Gender-Specific’ Cancers
Investigators studied whether sexual orientation affects screening for prevalent gender-specific cancers including prostate, breast, and cervical cancer.
Race Reporting in GU Cancers Indicates Relative Overrepresentation of White Individuals
Lythgoe et al studied patterns of race reporting in genitourinary (GU)
cancer trials.
Bone-Targeted Therapies and Incidence of Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma
A retrospective analysis evaluated the incidence of ONJ in patients who received VEGF-TKIs or immune-oncology therapy for mRCC and bone-targeted therapies for bone metastases.
Effect of Hypertension History on Outcomes in Patients With Metastatic Renal Cell Carcinoma
A retrospective analysis sought to determine the effect of hypertension on overall survival, response, and progression-free survival in patients with mRCC.
NLR Rise May Predict Mortality, Treatment Failure Risks in mRCC
A rise in neutrophil-to-lymphocyte ratio of 3 or more after 2 months of therapy is associated with an increased risk for death in less than 1 year and treatment failure in less than 6 months, according to investigators.
HIF-2α Inhibitor/Cabozantinib Doublet Active in Previously Treated Advanced ccRCC
Choueiri et al tested the efficacy of the investigational hypoxia-inducible factor 2α (HIF-2α) inhibitor in combination with cabozantinib.
-
Loading...
-
Loading...
Next post in ASCO GU 2021
